These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12756087)

  • 1. Chemotherapy of prostate cancer: present and future.
    Trump D; Lau YK
    Curr Urol Rep; 2003 Jun; 4(3):229-32. PubMed ID: 12756087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update in the management of patients with hormone-refractory prostate cancer.
    Moore CN; George DJ
    Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for prostate cancer.
    Gilligan T; Kantoff PW
    Urology; 2002 Sep; 60(3 Suppl 1):94-100; discussion 100. PubMed ID: 12231060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies in chemotherapy of prostate cancer.
    Heicappell R
    Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for chemotherapy in prostate cancer?
    Canil CM; Tannock IF
    Br J Cancer; 2004 Sep; 91(6):1005-11. PubMed ID: 15150548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
    Eisenberger MA; Antonarakis ES
    Urol Clin North Am; 2012 Nov; 39(4):573-81. PubMed ID: 23084532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current chemotherapeutic approaches for androgen-independent prostate cancer.
    Rumohr JA; Chang SS
    Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?
    Milowsky MI; Nanus DM
    Cancer Invest; 2002; 20(5-6):849-50. PubMed ID: 12197243
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment options in hormone-refractory prostate cancer: current and future approaches.
    Harris KA; Reese DM
    Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy for prostate cancer].
    Medioni J; Dionysopoulos D; Banu E; Scotté F; Beuzeboc P; Oudard S
    Presse Med; 2008 May; 37(5 Pt 2):814-20. PubMed ID: 18160251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy for prostate cancer].
    Itoh N
    Nihon Rinsho; 2005 Feb; 63(2):293-7. PubMed ID: 15714981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What next after hormonotherapy in cancer prostate?
    Parvez T; Al-sisi H; Ibraheim I
    J Coll Physicians Surg Pak; 2003 Oct; 13(10):606-10. PubMed ID: 14588180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D
    BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabazitaxel in prostate cancer: stretching a string.
    Dorff TB; Quinn DI
    Lancet; 2010 Oct; 376(9747):1119-20. PubMed ID: 20888974
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.
    Autorino R; Di Lorenzo G; Damiano R; De Placido S; D'Armiento M
    Urol Int; 2003; 70(1):1-14. PubMed ID: 12566808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.